How much funding has Persevere Therapeutics raised?

Persevere Therapeutics has disclosed $1.6M raised across 1 round.

Where is Persevere Therapeutics headquartered?

Persevere Therapeutics is headquartered in Chesterbrook, US.

Persevere Therapeutics

Chesterbrook, US · Founded 2025 · Delaware corporation

Find your way into Persevere Therapeutics

143 people in our graph share verified history with the Persevere Therapeutics team — schools, employers, funds. One of them is your warm intro.

Andrew Muirunlockedknows Greg Bosch · together at PuriCore (overlapped)

×3knows the team · via PuriCore

×4knows the team · via DePaul Driehaus College of Business

×2knows the team · via University of California, Irvine - The Paul Merage School of Business

knows the team · via Duke University

knows the team · via Geistlich Pharma North America

Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.

Biotech Healthtech Medical Devices

Founders & leadership

Greg Bosch Founder & CEOGreg Bosch is a life sciences executive who previously served as chairman and CEO of Panavance Therapeutics and CEO of Geistlich Pharma North America, where he led regenerative medicine efforts in the dental sector. He spent over two decades at Baxter International in roles including VP of Strategic Planning and General Manager of the BioSurgery Business, holds a B.A. in Public Policy from Duke University and an M.B.A. from DePaul University.

Reported raises · per SEC filings

Form D private placements

$1.6M disclosed across 1 round · 2026

▶$1.6MraisedMar 2026 · 12 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Greg BoschExecutive Officer, Director

Offering amount: $5M
Amount sold: $1.6M
First sale: Feb 2026
Incorporated: Corporation, Delaware, 2025
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Sapience Therapeutics4 shared keywordsSapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.

Jupiter Bioventures4 shared keywordsJupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas. The company is led by a team of experienced scientists and executives with a track record of creating approved drugs and founding successful biotech companies.

Coya Therapeutics3 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.

C4 Therapeutics3 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.

Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with Persevere Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Leadership - Persevere Therapeutics : Persevere Therapeuticsperseveretherapeutics.com · Sep 2021

Frequently asked questions

What does Persevere Therapeutics do?: Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
How much funding has Persevere Therapeutics raised?: Persevere Therapeutics has disclosed $1.6M raised across 1 round.
Where is Persevere Therapeutics headquartered?: Persevere Therapeutics is headquartered in Chesterbrook, US.